Stellenbosch 中国体育彩票 has commenced a groundbreaking clinical trial targeting preeclampsia, a life-threatening pregnancy complication that claims thousands of lives globally each year.
On November 13, researchers at the Preeclampsia Research Unit enrolled their first participant—a woman experiencing preeclampsia complicated by severe hypertension—in the DM199 for Pregnancy Complications study. Led by Professor Cathy Cluver, the trial represents a potential turning point in addressing a condition that has seen little therapeutic innovation for decades.
“This is the first time we've been able to test a new drug for preeclampsia treatment," Cluver said. “DM199 shows remarkable potential."
Preeclampsia is a severe disorder affecting about 5% of all pregnancies. Preeclampsia results in the death of more than 70 000 women and half a million foetal deaths annually. Characterised by high blood pressure with end organ damage, the condition develops in the second half of pregnancy and poses significant risks to both mother and child.
The novel drug, DM199, is a synthetic version of tissue-kallikrein-1, a natural protein designed to address the root cause of preeclampsia: endothelial dysfunction. Unlike current treatments that only manage blood pressure, DM199 aims to improve blood vessel health and potentially prevent catastrophic complications.
A key advantage of the drug is its molecular structure. As a large protein molecule, DM199 is unlikely to cross the placental barrier, offering a unique safety profile that distinguishes it from existing antihypertensive medications.
The trial will proceed in carefully monitored stages. Initially, researchers will conduct a “dose finding" study, treating three women consecutively and incrementally increasing the dosage to determine the most effective and safe concentration.
“We're starting with an ultra-low dose and will closely monitor for safety," Cluver explained. “Our primary goals are to establish an appropriate dosage and ensure the drug does not impact the unborn child."
This research addresses a critical gap in medical research. Historically, fears of potentially harming unborn babies have discouraged pharmaceutical development for pregnancy-related complications, effectively leaving pregnant women with complex conditions as “drug orphans".
The trial represents a significant step forward in maternal healthcare, offering hope for a more targeted and effective approach to managing one of pregnancy's most dangerous complications.
?Image credit: Freepik
